The EPITOPE study is designed to evaluate the safety and efficacy of a novel desensitization method, called EPicutaneous ImmunoTherapy (EPIT) with the Viaskin® Peanut patch in young children aged between 1-3 years and diagnosed with peanut allergy.
Is my child eligible to participate?
Your child can take part in this study if they:
- Are between 1-3 years of age, and
- Have been diagnosed with a peanut allergy.
If you answered ‘YES’ to the two questions above, you may contact the Immunology Research team at The Kids Research Institute Australia to learn more about the EPITOPE Study at FoodAllergyResearch@health.wa.gov.au.
What happens if my child qualifies?
If your child qualifies for the study, you will receive:
- Study-related procedures and exams at no cost, and
- Compensation for your time.
Where can I learn more?
Please reach out to the EPITOPE Team at FoodAllergyResearch@health.wa.gov.au. You can also learn more about the EPITOPE study by searching the ClinicalTrials.gov website.